Enovis Corporation (ENOV) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, ENOV scores 44 out of 100, a D grade labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC of -32.7% and FCF yield of 1.51%); Whale 13F Flow at 12/20 (institutional accumulation and options positioning); Insider Conviction at 8/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 6/20 (beta of 1.0 and sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z of 0.2, Piotroski F of 7/9, Debt/Equity of 0.85).

For a prospective investor, the weakest pillars are the cash engine and insider conviction, while institutional positioning is the relative bright spot. The low ROIC and Altman Z-Score point to a business that has not yet converted capital into returns and sits in a financially stressed zone. The Piotroski score of 7/9 suggests some internal financial-quality signals remain intact, which partially offsets the distress readings. Any upside case would depend on a turnaround in operating profitability that the source data does not yet show. Valuation tradeoffs are difficult to assess because P/E and EV/EBITDA are not available in source data, and with negative operating margins, earnings-based valuation is not meaningful from the figures provided.

Enovis Corporation is listed on the NYSE and classified under the Health Care sector, within the Industrial Specialties industry, per the source profile. The source data does not describe its products, customers, or revenue model. Per the market data, the company reports a gross margin of 59.8%, but the source does not explain the underlying business activities that generate it.

Per the SEC financials, revenue rose from $1707.2M in FY 2023 to $2248.0M in FY 2025, while operating losses widened from $-65.7M to $-1124.2M over the same span. Market data reports an operating margin of -50% and a net margin of -52.7%. Per the Roarable RQD rating, ROIC is -32.7%, the Altman Z-Score is 0.2, and the Piotroski F-Score is 7/9. Debt/Equity is 0.85 per the same rating, and cash of $36.4M sits against debt of $1261.8M in FY 2025.

Per the recent news feed, there are five items tied to ENOV. Two are flagged RED under the RISK WATCH label: a Investing.com item headlined that UBS cut its price target on the acquisition impact, and a Stock Traders Daily item on risk zones. The remaining three are flagged YELLOW under MARKET WIRE, covering a general Yahoo Finance Singapore stock page, a TradingView estimates page, and a Seeking Alpha piece headlined that the stock screens cheap but faces a continued M&A overhang. A further Yahoo Finance item covers stock forecasts. The feed summaries are generic and do not provide detail beyond headlines. The butterfly supply-chain graph reports no supply chain and no proprietary signals.

• What products and services generate the $2248.0M in FY 2025 revenue, and what drove the operating loss?
• What acquisition is referenced in the UBS price target cut and the M&A overhang headlines, and how is it financed?
• What are the EPS, P/E, and EV/EBITDA figures, given that these are absent from the source data?
• How does the company plan to cover $1261.8M of debt against $36.4M of cash, and what is the maturity profile?
• What institutional, insider, and analyst positioning exists beyond the aggregate pillar scores?